[Edaily Starin KIM HYUNSIK Reporter] The new ballad unit “DIMENSION” from the 24-member girl group tripleS is set to debut. (Photo: Mode House)
Their agency, Mode House, announced on the 24th, “We have confirmed four members—Jubin, Seoyeon, Sion, and Seoa—as members of tripleS’s new ballad dimension.” tripleS is a group that creates and promotes various “dimensions” based on the results of the fan vote “Gravity.” Mode House held “Gravity,” a fan vote to select members for the Ballad Dimension, on its official app COSMO over four days from the 20th to the 23rd. As a result, Seo-yeon, Sion, and Seo-ah were selected to join the group, while Ju-bin was named as a “Mode House Pick” member. Previously, Triple S had launched its first ballad dimension, Aria, consisting of five members: Lee Ji-woo, Kim Chae-yeon, Kaede, Seo Da-hyun, and Nien. The group’s second Ballad Dimension will release a digital single, make their official debut, and appear on music shows. The group name and single release date will be announced at a later time. Mode House stated, “The four members selected as finalists will showcase a musical style distinct from that of Aria.” Triple S is currently appearing on the WonderK reality show “Badge War Season 4: Trust No One.” They will kick off their new world tour, “ANDLESS,” over two days, the 10th and 11th of next month, at the Jangchung Gymnasium in Seoul. They will then continue the tour, visiting Macau, Tokyo, Toronto, New York, Chicago, Dallas, Los Angeles, and Vancouver.
This week (October 6–8), startups across various sectors—including defense, biotech, and artificial intelligence (AI) image-generation platforms—secured investments from venture capital (VC) firms and…
SK Group Chairman Choi Tae-won announced plans to establish a semiconductor production hub in the Honam region that would be two-thirds the size of the Yongin Semiconductor Cluster. He also left open …
South Korea’s pharmaceutical and biotech stocks posted mixed results on Oct. 8, with Peptron plunging nearly 30% after its technology evaluation with Eli Lilly concluded without a follow-on commercial…